IVERIC bio Receives FDA Agreement Under an SPA for GATHER2 Phase 3 Clinical Trial of Zimura®

IVERIC bio GATHER2 Trial of Zimura® for Geographic Atrophy 
IVERIC Bio (ISEE) announced that it received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) for the overall design of GATHER2, the pivotal clinical trial of IVERIC product Zimura® (avacincaptad pegol) for the treatment of . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.